Vaccine studies using the Vaccine Research Registry

This page lists the NIHR supported vaccine studies that are currently approved to use the Vaccine Research Registry and that you may receive contact about.

From December 2020 all study invitations from the vaccine research registry will be sent to you from NHS COVID-19 Vaccine Research Registry (ccsm@nhsdigital.nhs.uk). Please note however that if you complete a pre-screener for a study, any follow up emails will be from the study team this will be an ac.uk; nhs.uk; nhs.net; nihr.ac.uk address.

We still need your help

There is no change to any of the number of clinical trials into COVID vaccines at the moment, and it is essential that these continue.

We will need data about a number of vaccines and their safety and effectiveness, in order to protect the population. No one vaccine is likely to be suitable for everyone, the first vaccine may not be the most effective and easiest to use, and we must make sure that the other studies continue to allow us to have a selection of vaccines to protect the whole population.

Studies looking for volunteers

There are currently no COVID-19 vaccine studies recruiting volunteers through the NHS COVID-19 Vaccine Research Registry. However there are a number of studies which will soon be using the registry to find participants. Please keep referring to this page over the next few weeks to discover more studies looking for volunteers.

Studies that are now closed for recruitment

The studies listed below have previously used the NHS COVID-19 Vaccine Research Registry to help identify suitable participants. These vaccine studies have now reached their recruitment target and their results are helping us to learn more about the effectiveness of COVID-19 vaccines.

Novavax study

The purpose of this study is to test a new vaccine against COVID-19 and we are looking for volunteers to take part.  If you are aged 18-84 and in good health, you could be eligible to participate.  The study involves 6 visits over a period of around 13 months.  This study is being conducted across multiple locations in the UK.

When will this study contact me?

Contact from this study was approved to start from 1 October 2020. You will be contacted if you fit the volunteer criteria the study team is currently looking for, and if you live in one of the locations where hospitals are currently looking for volunteers for this study. 

What email address will be used to contact me about this?

You will receive an email notification from Novavax Covid 19 Vaccine Study (ccsm@nhsdigital.nhs.uk)If you decide you are interested in the study and complete the pre-screening, then the study team may contact you directly from a different email address - this will be an ac.uk; nhs.uk; nhs.net; nihr.ac.uk.  

To see if you can take part in this study visit the study screening website.

Oxford study

The COVID-19 Oxford Vaccine Trial aims to find a safe vaccine that can be used to create immune responses against the virus and thus prevent the disease. The study involved healthy volunteers aged 56 years and over who will attend 7 visits over 13 months.  If you volunteered, you will be contacted if you fit the volunteer criteria the study team is currently looking for, and if you live in one of the locations where hospitals are currently looking for volunteers for this study. 

What email address will be used to contact me about this?

You will receive an email notification from oxfordvaccinestudy@nhs.net. If you decide you are interested in the study and complete the pre-screening, then the study team may contact you directly from a different email address - this will be an ac.uk; nhs.uk; nhs.net; nihr.ac.uk.  

PROVENT Study

The PROVENT Study is researching a combination of two investigational monoclonal antibodies for the prevention of COVID-19. We are looking for volunteers who are 18 years of age and older and at an increased risk of exposure to COVID-19 (due to location, employment, or personal circumstances) to take part. The study involves 8 visits over 1 year and is being conducted at multiple locations in the UK.

When will this study contact me?

Contact from this study was approved to start from 18 December 2020. You will be contacted if you fit the volunteer criteria the study team is currently looking for, and if you live in one of the locations where hospitals are currently looking for volunteers for this study. 

What email address will be used to contact me about this?

You will receive an email notification from the PROVENT COVID-19 Study at ccsm@nhsdigital.nhs.uk. If you decide you are interested in the study and complete the pre-screening, then the study team may contact you directly from a different email address ‒ this will be an ac.uk, nhs.uk, nhs.net, or nihr.ac.uk email address.  

To see if you can take part in this study, visit www.c19PROVENTstudy.com.

Valneva Study

A new COVID-19 vaccine study is starting and looking for healthy adult volunteers to participate.  The study is sponsored by Valneva Austria GmbH. The major eligibility criteria are as follows:

-        Between 18 to 55 years of age

-        Generally healthy with a Body Mass Index (BMI) of 18-30

The study, VLA2001-201, is testing a new vaccine candidate to prevent COVID-19 across several hospitals in the UK. The study is evaluating the investigational vaccine to confirm that it is safe and tolerable for the users.

If you take part in this study, you will receive the investigational vaccine either in the low, medium or high concentration dose at no costs and you will be compensated for your time.

There will be a screening visit, two vaccination visits, 3 weeks apart and a number of follow-up visits to attend. Study related activities will include physical examination, COVID-19 testing, blood and urine samples. In total, your participation is required for about 7 months.

Comparing COVID-19 Vaccine Schedule Combinations (Com-COV) Study

We are recruiting people 50 years of age and over to a study of ‘mixed’ schedules of different COVID-19 vaccines.

There are now a number of vaccines that have been approved to prevent COVID-19 in the UK. These use two-doses, a ‘prime’ first dose, followed by a ‘boost’ second dose some weeks later. The purpose of this trial is to see how well people’s immune systems respond when they are primed with one type of vaccine, then boosted with another and to see how good the response is when the second dose is separated from the first dose by different periods of time.

The trial will take one year to complete per participant (from the time the first dose of vaccine is given).

If you are interested in finding out more, please visit our website: www.comcovstudy.org.uk where you can access the Study Information Booklet and complete a screening questionnaire.

Janssen COVID-19 Study

Janssen is recruiting volunteers for a COVID-19 vaccine study in the UK. The purpose of this clinical study is to determine the efficacy (whether it works) and safety of an investigational vaccine for the prevention of COVID-19.

This investigational vaccine is being evaluated in people 18 years of age or older.

For more information, or to find out if you are eligible to volunteer, visit: https://gb.ensemblestudy.com

When will the study contact me?

Contact for this study was approved to start from November 10th 2020. You will be contacted if you fit the volunteer criteria the study team is currently looking for, and if you live in one of the locations where hospitals are currently looking for volunteers for this study.

What email address will be used to contact me about this?

You will receive an email notification from ccsm@nhsdigital.nhs.uk. If you decide you are interested in the study and complete the pre-screening, then the study team may contact you directly from a different email address - this will be an ac.uk; nhs.uk; nhs.net; nihr.ac.uk.